

Haematologica
HAEMATOL/2018/211235
Version 3

Persistence with generic imatinib for chronic myeloid leukemia: a
matched cohort study

Adi J. Klil-Drori, Hui Yin, Laurent Azoulay, Michaël Harnois,
Michel-Olivier Gratton, Lambert Busque, and Sarit E. Assouline

Disclosures: Dr. Assouline reports grants from Rossy Cancer Network, during the conduct of the study; grants and personal fees from Roche, personal fees from BMS, personal fees from Pfizer, personal fees from Janssen, outside the submitted work. Dr. Busque reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, during the conduct of the study; personal fees from Celgene, outside the submitted work. All other authors have nothing to disclose.

Contributions: Adi J. Klil-Drori: conceptualization, data analysis, writing, review, and editing. Hui Yin: data analysis and review. Laurent Azoulay: conceptualization, data analysis, and review. Michaël Harnois, Michel-Olivier Gratton, and Lambert Busque: review. Sarit E. Assouline: data acquisition, conceptualization, writing, review, and study supervision.